MichaelShimMD

Gastroenterology • Oceanside, CA

Biliary Tract Disease, Hepatology & Liver Transplantation, Inflammatory Bowel Disease

Physician

Join to view full profile

Dr. Shim is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Shim's full profile

Already have an account?

Office
3923 Waring Rd
Ste A
Oceanside, CA 92056
Phone+1 760-724-8782

Fax+1 760-842-7801

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Gastroenterology, 2005 - 2008
NYU Grossman School of MedicineResidency, Internal Medicine, 2001 - 2004
New York University School of MedicineClass of 2001

Certifications & Licensure

CA State Medical License 2004 - 2026
NY State Medical License 2002 - 2005
American Board of Internal Medicine Gastroenterology
National Board of Physicians and Surgeons Gastroenterology
National Board of Physicians and Surgeons Internal Medicine

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Publications & Presentations

PubMed

38 citations
Severe hepatotoxicity due to Hydroxycut: a case report.
Michael Shim, Sammy Saab
Digestive Diseases and Sciences. 2009-02-01
1 citations
Multinodular fatty liver after herpes-zoster vaccine: case report and review of the literature.
Michael Shim, Francisco Durazo
Annals of Hepatology. 2008-10-01
42 citations
Susceptibility to hepatitis A in patients with chronic liver disease due to hepatitis C virus infection: missed opportunities for vaccination.
Michael Shim, Inessa Khaykis, James S. Park, Edmund J. Bini
Hepatology. 2005-09-01

Press Mentions

Polarean Imaging Reveals Successful Phase 3 Clinical TrialsJanuary 29th, 2020
Polarean Imaging Plc Announces Positive Results from Pivotal Phase III Clinical TrialsJanuary 29th, 2020
Leukotriene A4 Hydrolase Inhibition Improves Age-Related Cognitive Decline via Modulation of Synaptic FunctionNovember 25th, 2023

Professional Memberships